Dericip Retard 150 combines Etofylline (115 mg) and Theophylline (35 mg) in a sustained-release formulation designed to effectively manage respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Etofylline acts as a bronchodilator, helping to relax the airways and improve airflow, while Theophylline enhances breathing by reducing airway resistance. This dual-action medication provides prolonged relief from symptoms, making it an ideal choice for patients seeking improved respiratory function and quality of life.
Reviews
There are no reviews yet.